Patients should be instructed to tell the doctor about progression of infection, signs of infection (fever, sore throat, urinary tract pain, muscle ache) and wound during therapy or 12 months after the therapy has been stopped in order to adjust the dose and if re-administration is needed. Administration should be done carefully in the elderly, debilitated, patients with hypothyroidism/cirrhosis, myocardial infarction, asthma, psychosis, hypertension; liver function failure, myasthenia gravis patients taking anticholinesterase, thromboembolic disturbance, renal insufficiency, osteoporosis, ocular herpes simplex infection, increased intraocular pressure and seizure disturbance. There is a tendency for osteoporosis, therefore, administration in menopausal patients should be done carefully. Colergis should not be used in patients with peptic ulcer except in a very serious situation; also, be careful in patients with diverticulitis, colitis ulcer and intestinal anastomosis. It should not be administered in viral/bacterial infection that cannot be controlled by antibiotics unless in a very critical situation. Chemoprophylaxis should be included in managing patients with active tuberculosis history.
Effects on the Ability to Drive or Operate Machinery: May impair ability to drive or operate machinery (drowsiness, dizziness, weakness).
Use in children: If possible, long-term high-dose use in children should be avoided, since Colergis can decelerate bone growth; if long-term therapy is really needed, monitor on infants and children's growth and development should always be done. High-dose in children also causes acute pancreatitis, furthermore, it causes destruction of pancreas.